The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...
FDA Clears New Lung DrugThe US Food and Drug Administration has approved Jascayd (nerandomilast) tablets for adults with ...
The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.
The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...
In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...
Here are the top 5 most-read pulmonary fibrosis articles of 2025.
BuzzFeed on MSN
My Dad Has A Serious Illness. He Started Eating McDonald's And I Couldn't Believe What Happened Next.
Several years ago, my dad was diagnosed with pulmonary fibrosis. The news was a shock. At 84 years old, Daddy had been ...
Police Chief Thomas McClain has worked in Willard for more than 30 years. Despite a serious health diagnosis, he is resolved ...
Following the recent approval of nerandomilast tablets for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, the FDA has approved the medication for progressive pulmonary fibrosis as ...
Willard Police Chief Tom McClain has been in law enforcement for many decades, and has been the leader of Willard’s police force since 1993. He’s fought crime for years, ...
Detailed price information for Cspc Pharmaceuticals Group Ltd (CHJTF) from The Globe and Mail including charting and trades.
Boehringer Ingelheim's JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive pulmonary fibrosis (PPF) in adults.5 This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback